Novo Nordisk channels '70s 'Magic' in first TV ad for blockbuster-in-waiting Ozempic

Novo Nordisk
Novo Nordisk began its first advertising push for Ozempic this week with benefits set to the beat of a catchy '70s pop tune. (Novo Nordisk)

Novo Nordisk debuted its first DTC campaign for Type 2 diabetes drug Ozempic this week, setting the promotional stage for its aspiring blockbuster.

The TV ad launched Monday set to the tune of ‘70s hit pop song “Magic” by Pilot. However, Novo Nordisk switches up the key refrain “Oh, oh, oh, it’s magic” in the commercial to “Oh, oh, oh, Ozempic.” The earworm-y jingle for the GLP-1 drug repeats several times throughout the 90-second ad.

RELATED: Novo Nordisk tackles outcomes and affordability with pilot tying copays to adherence

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Meanwhile, typical patients in the TV ad reinforce the "Oh Ozempic" theme by exclaiming “Oh!” to different facts about Ozempic, including that the average weight loss seen in a recent study was up to 12 pounds and that the drug bears no increased risk of major cardiovascular events.

Novo's once-weekly injection was approved in December, but Novo is also working on a patient-friendly daily pill version. Analysts believe the drug is headed for blockbuster sales thanks to its weight loss and CV benefits, PBM coverage, market potential in China and strong doctor feedback. Market intelligence firm Evaluate estimates Ozempic sales of more than $2.2 billion by 2022.

RELATED: Novo Nordisk results show GLP-1s are job 1. Can its crucial Ozempic launch deliver?

Meanwhile, though, Ozempic is going head-to-head with Eli Lilly’s Trulicity, which currently boasts a 40% market share. Ozempic also competes with the Danish drugmaker's own Victoza, a shorter-lasting form of the drug. Novo is counting on Ozempic to catch the baton from daily-dosed Victoza as Lilly’s Trulicity and other longer-acting GLP-1 drugs angle for a share of that market.

Suggested Articles

Traditional generics bigwigs Teva, Mylan, Sandoz, Amneal and Endo have lost out to a group of six competitors in terms of U.S. weekly prescriptions.

Roche’s Tecentriq scored some big wins lately, including a pair of first-in-class approvals. But in other cancers, it's decided to pull the plug.

Biosims haven't worked, experts say. Instead, it's time to for an independent body to set fair biologic prices after the drugs lose exclusivity.